Last reviewed · How we verify
NCT05772741: 2253
Grafts of GSCs Into Brain Organoids for Testing Anti-invasion Drugs
NA trial testing Biological sample collection in Glioblastoma in 160 participants. Status unknown.
31 December 2023
Quick facts
| Lead sponsor | Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 160 |
| Start date | 3 December 2018 |
| Primary completion | 31 December 2023 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Biological sample collection — full drug profile →
Conditions studied
- Glioblastoma — all drugs for Glioblastoma →
- Glioma, Malignant — all drugs for Glioma, Malignant →
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Who can join
18 and older, any sex, with Glioblastoma or Glioma, Malignant. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In patients operated for glioblastoma, glioma stem-like cell lines will be obtained from tumor tissue, and IPSCs from skin fibroblasts or PBMCs. Brain organoids will be generated from IPSCs and co-cultured with IPSCs to study brain invasion and ciliogenesis. 3D genome architecture of glioma stem-like cells will be investigated. Gene modulation and pharmacologic strategies to inhibit invasion and restore ciliogenesis will be explored.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Organoids: The current status and biomedical applications.
Yang S, Hu H, Kung H, Zou R, et al · · 2023 · cited 162× · PMID 37215622 · DOI 10.1002/mco2.274 -
Tumour organoids and assembloids: Patient-derived cancer avatars for immunotherapy.
Mei J, Liu X, Tian HX, Chen Y, et al · · 2024 · cited 25× · PMID 38664597 · DOI 10.1002/ctm2.1656 -
Non-animal glioblastoma models for personalized treatment.
Zottel A, Jovčevska I, Šamec N. · · 2023 · cited 5× · PMID 37928397 · DOI 10.1016/j.heliyon.2023.e21070 -
Modeling Liver Development and Disease in a Dish.
Iqbal W, Wang Y, Sun P, Zhou X. · · 2023 · cited 4× · PMID 37958904 · DOI 10.3390/ijms242115921 -
Patient-Derived Ex Vivo Cultures and Endpoint Assays with Surrogate Biomarkers in Functional Testing for Prediction of Therapeutic Response.
Tsukamoto Y, Hirashita Y, Shibata T, Fumoto S, et al · · 2023 · cited 3× · PMID 37627132 · DOI 10.3390/cancers15164104
Verify or expand the search:
- PubMed search for NCT05772741
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Biological sample collection
Trials testing the same drug.
- NCT07483476 — Study of Cell-free DNA in Children and Adolescents With Acute Lymphoblastic Leukemia · not yet recruiting
- NCT06372054 — TORNADO-Omics Techniques and Neural Networks for the Development of Predictive Risk Models · recruiting
- NCT06068738 — Association of Ex Vivo Drug Response (EVDR) and Clinical Outcome in Ovarian Cancer · terminated
- NCT05787964 — Immunity to Infection in Healthy Participants and Participants With Cancer · active not recruiting
- NCT04873492 — From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis · NA · recruiting
Other recruiting trials for Glioblastoma
Currently open trials in the same condition.
- NCT07284069 — Senicapoc and Perampanel for Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
- NCT05653635 — Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study · Phase 2 · recruiting
- NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
- NCT07448480 — Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas · active not recruiting
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
Other Fondazione Policlinico Universitario Agostino Gemelli IRCCS trials
Trials by the same sponsor.
- NCT07514572 — Impact of Estimated Weight and Height on Nutritional Assessment in Elderly · NA · not yet recruiting
- NCT07504679 — Adipose Visceral and Epicardial Risk Evaluation · NA · not yet recruiting
- NCT07520643 — MISTIC Study: Atherosclerosis, Neurocognition & Cardiovascular Signaling · not yet recruiting
- NCT07479238 — Breath Test-Based Assessment of SIBO in Chronic Pancreatitis and Partial Pancreatectomy · not yet recruiting
- NCT07494227 — Development of the SC-IBD Self-Care Measurement Scale · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05772741 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Last refreshed: 16 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05772741.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing